The early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV
infection has been compromised to some extent by rapid development of multidrug-resistant …

The conformational restriction (rigidification) of a flexible ligand has often been a commonly
used strategy in drug design, as it can minimize the entropic loss associated with the ligand …

Human immunodeficiency virus (HIV) is the etiological agent of acquired immunodeficiency
syndrome (AIDS). Nowadays, FDA has approved over thirty antiretroviral drugs grouped in …

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) nowadays represent very potent
and most promising anti‐AIDS agents that specifically target the HIV‐1 reverse transcriptase …

We designed and synthesized a series of human immunodeficiency virus type 1 (HIV-1) non-
nucleoside reverse transcriptase inhibitors (NNRTIs) with a piperidine-substituted thiophene …

In our arduous efforts to develop new potent HIV-1 non-nucleoside reverse transcriptase
(RT) inhibitors (NNRTIs), novel piperidine-linked [1, 2, 4] triazolo [1, 5-a] pyrimidine …

HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) nowadays represent most
promising anti-AIDS drugs that specifically inhibit HIV-1 reverse transcriptase (RT). They …

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are very potent and most
promising anti-AIDS drugs that specifically inhibit HIV-1 reverse transcriptase (RT) …

A novel series of dihydrofuro [3, 4-d] pyrimidine (DHPY) analogs have recently been
recognized as promising HIV-1 non-nucleoside reverse transcriptase (RT) inhibitors …

HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) have been playing an
important role in the fight against acquired immunodeficiency syndrome (AIDS) …